FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug...
BOTHELL, Wash., Jan. 20 -- SCOLR Pharma, Inc. (Amex: DDD) today announced that the U. S. Food and Drug Administration (FDA) has issued a Complete Response letter for its Abbreviated New Drug...
View ArticleCelestial Biologicals collaborates with GE Healthcare to set up India’s first...
Major boost to patients with blood/immune disorders or severe blood loss India could save foreign exchange equivalent of US$ 15 million through local manufacturing of plasma products Investment of US$...
View ArticlePfizer to Acquire Wyeth, Creating the World s Premier Biopharmaceutical Company
Diversification, Flexibility and Scale Position New Company for Success in Dynamic Global Health Care Environment Establishes Leadership in Human, Animal, and Consumer Health, including Primary and...
View ArticleHelsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to...
Today the Swiss pharmaceutical group Helsinn announced the acquisition, of the US biopharmaceutical company, Sapphire Therapeutics Inc. with headquarters in Bridgewater, New Jersey, for an undisclosed...
View ArticleAlnylam Provides Update on Kreutzer-Limmer Patent Family
CAMBRIDGE, Mass.--Jan. 20, 2009--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has ruled in favor of the...
View ArticleIpsen announces the signature of a co-promotion agreement with Novartis for...
Ipsen (Euronext:IPN) announced today that it has signed an agreement with Novartis for the co-promotion in France of the antihypertensive drug Exforge®. Already in partnership with Novartis since 2003...
View ArticleGen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
- Companies Will Work Together to Protect World's Supply of Donated Blood from Infectious Diseases Until 2025 - Partners Anticipate Continued Expansion into New Global Markets and Development of...
View ArticleAstellas Proposes to Acquire CV Therapeutics for $16 per Share in Cash
Tokyo, Japan, January 27, 2009 -- Astellas Pharma Inc. (“Astellas”) today announced that it has submitted a proposal to the Board of Directors of CV Therapeutics, Inc. (Nasdaq: CVTX) to acquire all...
View ArticleA Milestone in Cancer Genetics: deCODE Discovers First Common Genetic...
Findings point to common mechanisms of susceptibility to cancers of the lung, bladder, prostate, cervix and skin; findings to be integrated into deCODEme(TM), the new deCODEme Cancer Scan(TM), and...
View ArticleAxikin Pharmaceuticals Spins out of Actimis
SAN DIEGO, Jan. 22 -- Axikin Pharmaceuticals, Inc., a startup company dedicated to developing and commercializing small molecule therapeutics for respiratory and inflammatory diseases, today announced...
View Article
